- Home
- IFRX vs FONR Comparison
IFRX vs FONR Comparison
Compare IFRX & FONR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- FONR
- Stock Information
- Founded
- IFRX 2007
- FONR 1978
- Country
- IFRX Germany
- FONR United States
- Employees
- IFRX N/A
- FONR N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- FONR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- IFRX Health Care
- FONR Health Care
- Exchange
- IFRX Nasdaq
- FONR Nasdaq
- Market Cap
- IFRX 117.8M
- FONR 100.2M
- IPO Year
- IFRX 2017
- FONR 1987
- Fundamental
- Price
- IFRX $1.83
- FONR $14.75
- Analyst Decision
- IFRX Strong Buy
- FONR
- Analyst Count
- IFRX 1
- FONR 0
- Target Price
- IFRX $8.00
- FONR N/A
- AVG Volume (30 Days)
- IFRX 498.3K
- FONR 17.9K
- Earning Date
- IFRX 03-20-2025
- FONR 02-18-2025
- Dividend Yield
- IFRX N/A
- FONR N/A
- EPS Growth
- IFRX N/A
- FONR N/A
- EPS
- IFRX N/A
- FONR 1.17
- Revenue
- IFRX $187,930.00
- FONR $101,570,089.00
- Revenue This Year
- IFRX $396.02
- FONR N/A
- Revenue Next Year
- IFRX $155.22
- FONR N/A
- P/E Ratio
- IFRX N/A
- FONR $12.56
- Revenue Growth
- IFRX 177.12
- FONR N/A
- 52 Week Low
- IFRX $1.17
- FONR $14.05
- 52 Week High
- IFRX $2.82
- FONR $23.41
- Technical
- Relative Strength Index (RSI)
- IFRX 32.97
- FONR 37.71
- Support Level
- IFRX $1.76
- FONR $14.63
- Resistance Level
- IFRX $1.98
- FONR $17.62
- Average True Range (ATR)
- IFRX 0.19
- FONR 0.53
- MACD
- IFRX -0.08
- FONR -0.16
- Stochastic Oscillator
- IFRX 6.65
- FONR 4.03
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About FONR Fonar Corporation
Fonar Corp is a United States-based company which is engaged in the business of designing, manufacturing, selling and servicing magnetic resonance imaging (MRI) scanners, which utilize MRI technology for the detection and diagnosis of human disease, abnormalities, other medical conditions, and injuries. The company operates through two segments namely Manufacturing and servicing of medical equipment; and the Management of diagnostic imaging centers, which generates a vast majority of the revenue.